The heart beats through a coordinated sequence of electrical impulses. At rest, cardiac cells maintain a negative electrical charge inside the cell membrane, known as the resting membrane potential. When an impulse arrives, rapid ion shifts across the cell membrane create an action potential, triggering myocardial contraction.
An arrhythmia occurs when this normal electrical pathway is disturbed. Disruptions stem from abnormal impulse formation, such as irritable ectopic pacemakers, or abnormal impulse conduction, like re-entrant loops where an impulse circles endlessly. Recognizing these triggers helps nurses understand why specific medications are ordered to restore a normal sinus rhythm.
Antiarrhythmic medications are organized using the Vaughan Williams classification system, which groups drugs primarily by their dominant electrophysiological mechanism on the cardiac action potential.
Class I drugs block cardiac sodium channels, slowing the rapid depolarization phase of the action potential. This category is subdivided into three groups based on how strongly they bind to the channel and how they affect repolarization:
A common clinical observation is that strong sodium blockade can paradoxically worsen arrhythmias or depress myocardial contractility in damaged hearts.
Beta-blockers blunt the effect of catecholamines like adrenaline on the heart. By competitive antagonism at beta-1 receptors, they decrease automaticity in the SA node, slow conduction velocity through the AV node, and reduce myocardial contractility.
These properties make beta-blockers highly effective for controlling heart rates in supraventricular tachycardias and preventing adrenergic-triggered ventricular arrhythmias. Common agents include metoprolol and propranolol.
Class III drugs prolong the action potential and extend the refractory period by blocking potassium channels during repolarization. Because heart muscle cells remain refractory longer, they cannot be prematurely stimulated by stray electrical impulses.
Amiodarone is the most widely used drug in this class, though it also possesses properties of sodium, calcium, and beta-blockers. Because amiodarone accumulates in body tissues, nurses must monitor patients for multi-organ side effects, including pulmonary toxicity and thyroid dysfunction.
Class IV drugs are non-dihydropyridine calcium channel blockers, specifically verapamil and diltiazem. They inhibit the influx of calcium ions through L-type channels, primarily in the SA and AV nodes.
This action slows AV nodal conduction and prolongs AV nodal refractoriness, making these drugs ideal for terminating re-entrant supraventricular tachycardias that depend on the AV node for propagation. They should be used cautiously in patients with pre-existing heart failure due to their negative inotropic effects.
Several agents do not fit standard Vaughan Williams classes but play vital roles in managing rhythm disorders:
Administering antiarrhythmic therapy requires rigorous clinical vigilance because these drugs can provoke new arrhythmias or worsen existing ones. Nurses must continuously monitor cardiac telemetry for changes in heart rate, rhythm, and intervals such as the PR, QRS, and QT durations.
Baseline and ongoing assessments must include blood pressure, serum electrolyte levels, renal function, and hepatic panels. For drugs like amiodarone, periodic thyroid and pulmonary function tests are also required to catch organ toxicity early.